AZD1222(ChAdOx1 nCoV-19)疫苗接种后血栓形成伴血小板减少症:病例特征与关联
基于AstraZeneca全球安全数据库截至2021年4月26日的报告,检索接种AZD1222后同时报告血小板减少和血栓形成的病例,由专家依据现有TTS标准判定为「典型」「可能」「否」或「未知」。共识别573份报告,其中273份(47.6%)为「典型」、171份(29.8%)为「可能」TTS,合计444例;中位发病时间12.0天,总病死率22.2%(127/573),「典型」/「可能」TTS病死率23.6%(105/444),从2月/3月的39.0%(60/154)降至4月的15.5%(45/290)。首剂接种后「典型」/「可能」TTS报告率为每百万接种者7.5例。
要点
- 首剂接种后「典型」/「可能」TTS报告率为每百万接种者7.5例,后续剂次包括加强剂报告极少。
- 「典型」/「可能」TTS共444例,中位年龄50.0岁(IQR 38.0-60.0),275例(61.9%)为女性。
- 「典型」/「可能」TTS病死率23.6%(105/444),从2月/3月的39.0%(60/154)降至4月的15.5%(45/290)。
核心结论
- 本数据集中首剂接种后「典型」/「可能」TTS报告率为每百万接种者7.5例,后续剂次包括加强剂报告极少。
- 报告高峰与媒体驱动的关注一致,病死率下降与诊断/治疗指南的知晓度和发表增加相关。
- 与参考人群的病史差异提示可能存在未识别的危险因素。
- 判定受未报告参数限制,已开发算法用于分类潜在TTS病例,全面报告有助于进一步改进定义和管理。
研究设计与样本
- 检索AstraZeneca全球安全数据库(截至2021年4月26日)中接种AZD1222后同时报告血小板减少和血栓形成的病例,使用标准化MedDRA查询/高层术语。
- 病例由专家依据现有TTS标准判定为「典型」「可能」「否」或「未知」。
- 评估了补充确证数据集(5月20日至6月20日、10月1日至12月28日)。
主要发现
- 共识别573份报告,其中273份(47.6%)为「典型」、171份(29.8%)为「可能」TTS,合计444例。
- 444例中275例(61.9%)为女性,中位年龄50.0岁(IQR 38.0-60.0)。
- 脑静脉窦血栓报告196例(44.1%),内脏静脉血栓65例(14.6%),多部位血栓119例(26.8%)。
- 中位发病时间12.0天(IQR 9.0-15.0)。
- 与疫情前参考人群比较,自身免疫性疾病(13.8% vs 4.4%)、既往肝素治疗(7.4% vs 1.2%)、血栓史(5.5% vs 1.4%)和免疫性血小板减少症(6.1% vs 0.2%)比例更高。
关键数值与推荐
- 首剂接种后「典型」/「可能」TTS报告率为每百万接种者7.5例。
- 总病死率22.2%(127/573),「典型」/「可能」TTS病死率23.6%(105/444)。
- 病死率从2月/3月的39.0%(60/154)降至4月的15.5%(45/290)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 判定受未报告参数限制。
- 已开发算法用于分类潜在TTS病例,全面报告有助于进一步改进定义和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-marketing surveillance for COVID-19 vaccines during the pandemic identified an extremely rare thrombosis with thrombocytopenia syndrome (TTS) reported post-vaccination, requiring further characterisation to improve diagnosis and management. METHODS: We searched the AstraZeneca Global Safety Database (through April 26, 2021) for cases with co-reported thrombocytopenia and thrombosis (using standardised MedDRA queries/high-level terms) following AZD1222 (ChAdOx1 nCoV-19). Cases were adjudicated by experts as 'typical','possible', 'no' or 'unknown' according to available TTS criteria. Additional confirmatory datasets (May 20-June 20, October 1-December 28) were evaluated. FINDINGS: We identified 573 reports, including 273 (47.6 %) 'typical' and 171 (29.8 %) 'possible' TTS cases. Of these 444 cases, 275 (61.9 %) were female, median age was 50.0 years (IQR: 38.0-60.0). Cerebral venous sinus thrombosis was reported in 196 (44.1 %) cases, splanchnic venous thrombosis in 65 (14.6 %) and thromboses at multiple sites in 119 (26.8 %). Median time to onset was 12.0 days (IQR: 9.0-15.0). Comparison with a pre-pandemic reference population indicated higher rates of autoimmune disorders (13.8 %, 4.4 %), previous heparin therapy (7.4 %, 1.2 %), history of thrombosis (5.5 %, 1.4 %), and immune thrombocytopenia (6.1 %, 0.2 %). Fatality rate was 22.2 % (127/573) overall and 23.6 % (105/444) in 'typical'/'possible' TTS, which decreased from 39.0 % (60/154) in February/March to 15.5 % (45/290) in April. Overall patterns were similar in confirmatory datasets. CONCLUSIONS: The reporting rate of 'typical'/'possible' TTS post first-dose vaccination in this dataset is 7.5 per million vaccinated persons; few cases were reported after subsequent doses, including booster doses. Peak reporting coincided with media-driven attention. Medical history differences versus a reference population indicate potentially unidentified risk factors. The decreasing fatality rate correlates with increasing awareness and publication of diagnostic/treatment guidelines. Adjudication was hindered by unreported parameters, and an algorithm was developed to classify potential TTS cases; comprehensive reporting could help further improve definition and management of this extremely rare syndrome.
引用
- Laffan MA, Rees S, Yadavalli M, et al. Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. Vaccine. 2022. PMID: 35989136. doi:10.1016/j.vaccine.2022.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。